{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:07:10Z","timestamp":1781305630871,"version":"3.54.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Capecitabine has been used for the treatment of various types of tumors. The rare side effects induced by capecitabine have been reported as hypertriglyceridemia, acute pancreatitis associated with hypertriglyceridemia and hypertriglyceridemia complicated with hyperglycemia. The mechanisms of capecitabine-induced hypertriglyceridemia are unclear. In this report, we present a subject with sigmoid colon cancer and capecitabine-induced dyslipidemia. LDL-cholesterol level was markedly elevated throughout the long period of treatment with capecitabine. In addition, triglyceride level was high and not stable during the treatment period. Her dyslipidemia was ameliorated by the treatment with 5 mg of rosuvastatin, which is one of the HMG-CoA reductase inhibitors.<\/jats:p>","DOI":"10.3389\/fonc.2021.664475","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T13:47:58Z","timestamp":1620136078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine"],"prefix":"10.3389","volume":"11","author":[{"given":"Takatoshi","family":"Anno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Yamatsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G348","article-title":"Capecitabine-Induced Severe Hypertriglyceridemia: Report of Two Cases","volume":"40","author":"Kurt","year":"2006","journal-title":"Ann Pharmacother"},{"key":"B2","article-title":"Capecitabine-Induced Hypertriglyceridemia: A Report of Two Cases","volume":"26","author":"Koutras","year":"2006","journal-title":"Anticancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0799-2","article-title":"Uncontrolled Hypertriglyceridemia Induced by Capecitabine: Case Report and Review of the Literature","volume":"63","author":"Bar-Sela","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903373708","article-title":"Hypertriglyceridemia: An Underdiagnosed Side Effect of Capecitabine Chemotherapy","volume":"49","author":"Orphanos","year":"2010","journal-title":"Acta Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000313517","article-title":"Cancer Chemotherapy and Cardiovascular Risks: Is Capecitabine-Induced Hypertriglyceridemia a Rare Adverse Effect","volume":"116","author":"Seminara","year":"2010","journal-title":"Cardiology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.52","article-title":"Severe Hypertriglyceridaemia During Treatment With Capecitabine","volume":"104","author":"Javot","year":"2011","journal-title":"Br J Cancer"},{"key":"B7","first-page":"104","article-title":"Severe Hypertriglyceridaemia Associated With the Use of Capecitabine","volume":"70","author":"Polinder-Bos","year":"2012","journal-title":"Neth J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.07.005","article-title":"The Clinical Importance of Recognizing Capecitabine-Induced Hypertriglyceridemia: A Case Report and Review of the Literature","volume":"12","author":"Leung","year":"2018","journal-title":"J Clin Lipidol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.07.07","article-title":"Capecitabine-Induced Hypertriglyceridemia: A Rare But Clinically Relevant Treatment-Related Adverse Event","volume":"9","author":"Uche","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"B10","article-title":"Hypertriglyceridaemia-Induced Pancreatitis: A Contributory Role of Capecitabine","volume":"18","author":"Chan","year":"2012","journal-title":"Hong Kong Med J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in Hypertriglyceridemic Pancreatitis: An Update","volume":"48","author":"Scherer","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2017.10.004","article-title":"Capecitabine-Induced Pancreatitits","volume":"150","author":"Cornejo-Uixeda","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02842.x","article-title":"Capecitabine-Induced Severe Hypertriglyceridaemia and Diabetes: A Case Report and Review of the Literature","volume":"26","author":"Garg","year":"2009","journal-title":"Diabetes Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000342382","article-title":"Capecitabine-Induced Hypertriglyceridemia and Hyperglycemia: Two Cases","volume":"90","author":"Duman","year":"2012","journal-title":"Pharmacology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214532508","article-title":"Hypertriglyceridemia and Hyperglycemia Induced by Capecitabine: A Report of Two Cases and Review of the Literature","volume":"21","author":"Han","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.diabres.2006.08.004","article-title":"Preheparin Serum Lipoprotein Lipase Mass Might be a Biomarker of Metabolic Syndrome","volume":"76","author":"Saiki","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5551\/jat.RV16003","article-title":"Postprandial Hyperlipidemia and Remnant Lipoproteins","volume":"24","author":"Masuda","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5551\/jat.13.55","article-title":"The Lipoprotein Fraction Between VLDL and LDL Detected by Biphasic Agarose Gel Electrophoresis Reflects Serum Remnant Lipoprotein and Lp(a) Concentrations","volume":"13","author":"Sato","year":"2006","journal-title":"J Atheroscler Thromb"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.664475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T13:48:01Z","timestamp":1620136081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.664475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":18,"alternative-id":["10.3389\/fonc.2021.664475"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.664475","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"article-number":"664475"}}